Literature DB >> 2952700

Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy.

P Spirito, B J Maron.   

Abstract

Development or progression of left ventricular hypertrophy has recently been described in children with hypertrophic cardiomyopathy. To determine whether similar changes in magnitude and distribution of left ventricular hypertrophy may also occur in adult patients with this disease, serial assessment of left ventricular wall thickness was obtained with M-mode and two-dimensional echocardiography in 65 patients with hypertrophic cardiomyopathy who were 23 to 50 years of age. The follow-up period was 3 to 6 years (mean 4). None of the 65 patients showed a substantial increase (greater than or equal to 5 mm) in left ventricular wall thickness; however, 9 (14%) demonstrated a substantial decrease (5 to 9 mm). Wall thinning most commonly involved the anterior ventricular septum (seven patients), but was also identified in the posterior septum (six patients), lateral free wall (two patients) and posterior free wall (one patient). In the nine patients with wall thinning, left ventricular end-diastolic diameter increased significantly (from 44 +/- 6 to 51 +/- 6 mm; p less than 0.001); however, in seven of the nine, absolute cavity size remained within normal limits (less than or equal to 52 mm) at the most recent evaluation. Eight of the nine patients with left ventricular wall thinning and relative cavity enlargement were severely symptomatic and one was mildly symptomatic. In conclusion, substantial progression of left ventricular hypertrophy was not identified in any of the study patients. Hence, if such progression occurs in adults with hypertrophic cardiomyopathy, it is probably rare. Conversely, an important minority of adult patients with hypertrophic cardiomyopathy may show progressive left ventricular wall thinning and relative cavity enlargement, which are usually associated with severe cardiac symptoms.

Entities:  

Mesh:

Year:  1987        PMID: 2952700     DOI: 10.1016/s0735-1097(87)80301-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Hypertrophic cardiomyopathy in the elderly.

Authors:  L M Shapiro
Journal:  Br Heart J       Date:  1990-05

2.  Hypertrophic cardiomyopathy: one man's family.

Authors:  R W Desanctis
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

Review 3.  Natural history of hypertrophic cardiomyopathy.

Authors:  P Spirito; P Bellone
Journal:  Br Heart J       Date:  1994-12

4.  CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.

Authors:  Sainan Cheng; Yeon Hyeon Choe; Hideki Ota; Chen Cui; Gang Yin; Minjie Lu; Lu Li; Xiuyu Chen; Sanjay K Prasad; Shihua Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2017-10-25       Impact factor: 2.357

5.  Novel ALPK3 mutation in a Tunisian patient with pediatric cardiomyopathy and facio-thoraco-skeletal features.

Authors:  Hager Jaouadi; Lilia Kraoua; Lilia Chaker; Alexandre Atkinson; Valérie Delague; Nicolas Levy; Rym Benkhalifa; Ridha Mrad; Sonia Abdelhak; Stéphane Zaffran
Journal:  J Hum Genet       Date:  2018-07-25       Impact factor: 3.172

6.  Late onset apical hypertrophic cardiomyopathy: a case report.

Authors:  Patrick Doeblin; Rolf Gebker; Burkert Pieske; Sebastian Kelle
Journal:  Eur Heart J Case Rep       Date:  2020-12-12

Review 7.  Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies.

Authors:  Riccardo Vio; Annalisa Angelini; Cristina Basso; Alberto Cipriani; Alessandro Zorzi; Paola Melacini; Gaetano Thiene; Alessandra Rampazzo; Domenico Corrado; Chiara Calore
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

8.  The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.

Authors:  Benedicte Jørgenrud; Mikko Jalanko; Tiina Heliö; Pertti Jääskeläinen; Mika Laine; Mika Hilvo; Markku S Nieminen; Markku Laakso; Tuulia Hyötyläinen; Matej Orešič; Johanna Kuusisto
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.